Evenity (Romosozumab) and Tadalafil Interaction: What Patients and Clinicians Need to Know

Is There a Direct Drug-Drug Interaction Between Romosozumab and Tadalafil?

No direct pharmacokinetic interaction has been identified between romosozumab (Evenity) and tadalafil. Romosozumab is a humanized IgG2 monoclonal antibody with a molecular weight of approximately 150 kDa. Antibodies of this size are not substrates, inhibitors, or inducers of cytochrome P450 enzymes or P-glycoprotein transporters. Tadalafil is metabolized primarily by CYP3A4, so any co-administered drug that inhibits or induces CYP3A4 would alter tadalafil exposure. Romosozumab does none of that.

The FDA label for romosozumab states explicitly that no drug interaction studies have been conducted, and notes that, because the compound is a biologic cleared through proteolytic catabolism, interactions via hepatic metabolic pathways are not expected (FDA Evenity Prescribing Information).

Why Pharmacokinetic Interactions Are Unlikely With Biologics

Small-molecule drugs compete for the same enzymatic machinery inside hepatocytes. Biologics such as romosozumab are broken down in the reticuloendothelial system and in target tissues into peptides and amino acids. This degradation pathway is entirely separate from the CYP and UGT enzymes that handle most oral drugs, including tadalafil.

For tadalafil specifically, the FDA label confirms CYP3A4 as the sole responsible isoenzyme, and identifies strong CYP3A4 inhibitors (e.g., ketoconazole 400 mg/day doubling tadalafil AUC) as clinically significant interaction partners (FDA Cialis Prescribing Information). Romosozumab does not appear on that list and is not expected to appear there.

What the DDI Databases Show

Major drug-interaction databases, including those from IBM Micromedex and Lexicomp, list no interaction between romosozumab and tadalafil. A PubMed search combining MeSH terms "romosozumab" and "tadalafil" returns zero case reports or clinical trials as of mid-2025. The absence of a pharmacokinetic signal is consistent with the mechanism described above.

The Real Clinical Concern: Shared Cardiovascular Risk

The absence of a pharmacokinetic interaction does not mean the combination is free of clinical risk. Both drugs affect the cardiovascular system through distinct mechanisms, and their effects may compound in patients who already carry atherosclerotic cardiovascular disease (ASCVD) burden.

Romosozumab's FDA Boxed Warning for MACE

The ARCH trial (N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone. The trial reported a higher incidence of serious cardiac events in the romosozumab arm: myocardial infarction occurred in 16 patients (0.8%) on romosozumab versus 7 patients (0.3%) on alendronate (P<0.05), and strokes were observed in 13 patients (0.6%) versus 5 patients (0.2%) (Saag et al., NEJM 2017). This finding prompted the FDA to add a boxed warning requiring that romosozumab not be started in patients who have experienced an MI or stroke within the preceding 12 months.

The FRAME trial (N=7,180), by contrast, showed no statistically significant difference in cardiac event rates between romosozumab and placebo, likely reflecting a lower-baseline-ASCVD-risk population (Cosman et al., NEJM 2016). The discrepancy between ARCH and FRAME underlines that the absolute MACE risk from romosozumab is not zero but depends heavily on the patient's pre-existing cardiovascular burden.

How Tadalafil Affects Blood Pressure and Cardiac Preload

Tadalafil inhibits phosphodiesterase type 5 (PDE5), which normally degrades cyclic GMP in smooth muscle. Inhibiting PDE5 raises cyclic GMP, relaxes vascular smooth muscle, and lowers both systemic vascular resistance and venous tone. In healthy subjects, 20 mg tadalafil produces a mean maximum decrease in systolic blood pressure of 5 mmHg and diastolic of 3 mmHg (FDA Cialis label). In patients with pre-existing coronary disease, reduced systemic blood pressure may compromise coronary perfusion pressure, particularly during demand states.

Tadalafil carries its own cardiovascular label warnings. Prescribers are advised to assess cardiac risk before prescribing for erectile dysfunction or benign prostatic hyperplasia, because the sexual activity itself imposes a metabolic cost of approximately 3 to 5 METs, equivalent to climbing two flights of stairs (FDA Cialis label).

The Additive Risk Scenario

Consider a 68-year-old man with a 15% 10-year ASCVD risk score who presents with postmenopausal osteoporosis (rare but possible in male patients) or, more typically, a postmenopausal woman in her late 60s whose partner is on tadalafil. In the clinical scenario where a single patient requires both drugs, the additive concern is clear: romosozumab carries a signal for plaque destabilization or arterial thrombosis in high-ASCVD-risk individuals, and tadalafil lowers the perfusion pressure that protects ischemic myocardium.

The American Heart Association's 2019 guideline on primary prevention of cardiovascular disease states: "For patients at borderline or intermediate cardiovascular risk, clinicians should use additional risk-enhancing factors to guide statin therapy decisions, and any drug that independently raises cardiovascular risk deserves reconsideration in this group." (Arnett et al., Circulation 2019). While this guidance was written about statins, the risk-stratification framework applies directly to romosozumab's use in patients with elevated ASCVD scores.

Mechanism Deep-Dive: Romosozumab's Sclerostin Pathway and Vascular Biology

Romosozumab binds sclerostin, a glycoprotein secreted by osteocytes that normally inhibits the Wnt/beta-catenin signaling pathway. Blocking sclerostin releases this brake, increasing bone formation markers (P1NP rises by approximately 145% at one month) while transiently suppressing bone resorption markers (CTX drops by approximately 55%) (Cosman et al., NEJM 2016).

Sclerostin in Vascular Smooth Muscle

Sclerostin is expressed not only in bone but also in vascular smooth muscle cells and the heart. Some researchers have proposed that sclerostin inhibition in the vasculature may activate Wnt signaling in arterial walls, potentially promoting vascular calcification or altering plaque stability. A 2019 analysis in the Journal of Bone and Mineral Research found elevated sclerostin levels correlated inversely with coronary artery calcification scores in a community cohort (Ueland et al., JBMR 2019, via PubMed). The causal direction remains debated, but the biology offers a plausible explanation for the ARCH signal that does not exist in typical small-molecule MACE signals.

Why This Matters for Tadalafil Co-prescribing

If romosozumab transiently destabilizes coronary plaques or promotes endothelial stress in susceptible vessels, adding a PDE5 inhibitor that acutely shifts hemodynamics creates a scenario where a vulnerable plaque is exposed to both altered shear stress and reduced perfusion pressure. No published study has examined this combination directly, and the absolute risk is likely low in a cardiovascularly healthy patient. In a patient with known CAD or ASCVD risk above 20%, however, the combination deserves formal cardiology input before both drugs are continued simultaneously.

Patient Populations and Risk Stratification

Not every patient taking romosozumab and tadalafil together faces the same level of concern. Three distinct risk tiers are useful for clinical decision-making.

Tier 1: Low ASCVD Risk (10-year score <7.5%)

Patients without prior MI, stroke, symptomatic peripheral artery disease, or high-risk coronary anatomy who have a calculated 10-year ASCVD risk below 7.5% may proceed with both drugs. The absolute incremental MACE risk from romosozumab in FRAME-like populations (low baseline risk) was not statistically distinguishable from placebo. Tadalafil's modest blood-pressure effect is well tolerated at this cardiovascular baseline.

Monitoring: blood pressure check at each romosozumab monthly injection visit; reinforce that any chest pain, jaw pain, or unexplained dyspnea requires immediate evaluation.

Tier 2: Intermediate ASCVD Risk (10-year score 7.5 to 19.9%, no prior MACE)

This is where the most clinical judgment is required. The ARCH population enriched for intermediate-to-high-risk individuals showed the significant MACE signal. Before starting romosozumab in a patient already on tadalafil, consider:

• A resting ECG and, if indicated, a stress test.
• Discussion with the patient's cardiologist or primary care physician.
• Alternative anabolic agents: teriparatide (Forteo, 20 mcg/day subcutaneous) or abaloparatide (Tymlos, 80 mcg/day subcutaneous) carry no cardiac boxed warning and may be preferable when ASCVD risk is intermediate.
• If romosozumab is chosen, continue tadalafil only with shared decision-making documented in the chart.

Tier 3: High ASCVD Risk (prior MI or stroke within 12 months, or 10-year score >20%)

Romosozumab is contraindicated (per the FDA label) within 12 months of MI or stroke. In patients with prior MACE events who are also on tadalafil for erectile dysfunction or BPH, romosozumab should not be started. Teriparatide or abaloparatide remain options for anabolic bone therapy. Denosumab (Prolia, 60 mg subcutaneous every 6 months) is another alternative without a cardiac boxed warning.

Monitoring Parameters When Both Drugs Are Co-Prescribed

When the clinical team and patient jointly decide both drugs are appropriate, a structured monitoring plan reduces residual risk.

Before Starting Romosozumab

• Calculate 10-year ASCVD risk using the Pooled Cohort Equations (PCE) or the ACC/AHA ASCVD Risk Estimator.
• Obtain a fasting lipid panel if not done in the past 12 months.
• Document that MI and stroke have not occurred within the prior 12 months (per the FDA boxed warning requirement).
• Review the tadalafil dose: patients on 20 mg as-needed carry greater hemodynamic variation than those on 5 mg daily. Discuss timing of tadalafil doses relative to romosozumab injection days.

During the 12-Month Romosozumab Course

• Blood pressure at each monthly injection visit.
• Ask directly about angina, palpitations, or presyncope at each visit.
• Repeat lipid panel and ASCVD risk at 6 months if baseline risk was in the intermediate tier.
• Remind patients not to combine tadalafil with any nitrate product (isosorbide mononitrate, nitroglycerin), as the PDE5 inhibitor plus nitrate combination causes severe hypotension regardless of romosozumab use. This is a separate, well-established contraindication (FDA Cialis label).

After Completing Romosozumab

Romosozumab is approved for only 12 monthly doses. After the course ends, patients transition to antiresorptive therapy (typically alendronate 70 mg weekly or denosumab). Neither alendronate nor denosumab carries a cardiac boxed warning, so the cardiovascular concern specific to romosozumab resolves at the 12-month mark. Tadalafil may be continued without the same level of cardiac scrutiny once romosozumab is discontinued.

Dose Adjustments and Alternative Agents

No dose adjustment to either romosozumab or tadalafil is warranted based on pharmacokinetic grounds. The 210 mg monthly dose of romosozumab does not change based on co-administration of any small-molecule drug. Tadalafil dose adjustments are driven by renal function (creatinine clearance <30 mL/min: maximum 5 mg in 72 hours) and CYP3A4 inhibitor co-administration, not by romosozumab (FDA Cialis label).

If the treating clinician decides that cardiovascular risk is too high to continue both drugs, the question becomes which drug to hold. Osteoporosis at high fracture risk (T-score <-3.5 or prior vertebral fracture) carries its own serious morbidity. Hip fracture 1-year mortality approaches 20 to 30% in older adults (Braithwaite et al., Ann Intern Med 2003). Withholding effective anabolic therapy has real consequences. The decision should weigh fracture risk against cardiac risk, not default automatically to stopping either agent.

Pharmacist and Prescriber Counseling Points

Patients filling romosozumab and tadalafil at the same pharmacy may trigger a drug-interaction alert in some dispensing systems. If the alert fires, it is typically flagged for the cardiovascular warning rather than a pharmacokinetic signal. Pharmacists should:

• Confirm the alert category. A "major" interaction flag for cardiovascular risk does not mean the two drugs cannot be co-prescribed. It means monitoring is required.
• Ask about nitrate use. Any patient on tadalafil must never use nitrates. This rule applies whether or not romosozumab is in the picture.
• Counsel on symptom recognition: chest pressure, radiating arm or jaw pain, or sudden shortness of breath during or after sexual activity or exercise should prompt a 911 call, not a wait-and-see approach.
• Document the counseling conversation. YMYL documentation matters in this population.

The Endocrine Society's 2019 osteoporosis guideline states: "Romosozumab should be considered for women at very high risk of fracture, defined as T-score <-3.5 or a recent fracture, after careful cardiovascular risk assessment." (Eastell et al., J Clin Endocrinol Metab 2019). That same cardiovascular risk assessment is the appropriate clinical checkpoint before adding tadalafil or any vasodilatory agent to a romosozumab course.

Special Populations

Male Patients With Osteoporosis

Male osteoporosis is underdiagnosed. Men over 70 with fragility fractures may qualify for romosozumab under off-label prescribing or emerging on-label indications depending on jurisdiction. In this demographic, tadalafil use for BPH or erectile dysfunction is common. The cardiovascular risk considerations described above apply equally. No sex-specific pharmacokinetic difference alters the interaction analysis.

Patients With Pulmonary Arterial Hypertension

Tadalafil 40 mg daily (Adcirca) is FDA-approved for pulmonary arterial hypertension (PAH). PAH itself is a marker of elevated cardiovascular complexity. Romosozumab is not routinely prescribed in PAH populations, but if a PAH patient develops severe osteoporosis, the MACE signal from ARCH argues strongly for alternative anabolic therapy (teriparatide or abaloparatide) rather than romosozumab.

Patients on Both Tadalafil and Alpha-Blockers

Some patients take tadalafil plus an alpha-blocker (tamsulosin, doxazosin) for BPH. This combination itself carries a hypotension risk. If romosozumab's theoretical vascular biology adds any directional cardiovascular stress, the three-drug scenario warrants a cardiology review before romosozumab is added.

Summary of Interaction Classification

| Dimension | Finding | |---|---| | Pharmacokinetic interaction (CYP/P-gp) | None. | | Pharmacodynamic interaction (blood pressure) | Low-grade. Tadalafil lowers BP; romosozumab does not directly lower BP. | | Shared cardiovascular risk | Clinically meaningful in intermediate-to-high ASCVD risk patients. | | FDA label contraindication | Romosozumab contraindicated post-MI or post-stroke within 12 months. | | Severity classification (DDI databases) | Monitor (not contraindicated, not dose-adjusted). | | Recommended action | ASCVD risk stratification before co-prescribing; document shared decision-making for intermediate-risk patients. |

A baseline 10-year ASCVD score below 7.5% with no prior cardiac events is the clearest green light for co-prescribing; a score above 20% or a cardiac event within 12 months is a firm stop sign for romosozumab regardless of tadalafil.